Chimerix Stock Price, News & Analysis (NASDAQ:CMRX)

$4.92 -0.05 (-1.01 %)
(As of 02/22/2018 11:36 AM ET)
Previous Close$4.92
Today's Range$4.91 - $5.07
52-Week Range$4.17 - $6.64
Volume110,900 shs
Average Volume256,875 shs
Market Capitalization$234.23 million
P/E Ratio-3.44
Dividend YieldN/A
Beta1.42

About Chimerix (NASDAQ:CMRX)

Chimerix logoChimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses. It is also advancing the development of CMX521 for the treatment and prevention of norovirus. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against all five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. Oral and IV formulations of brincidofovir are in development, both of which deliver the active antiviral directly to the site of viral replication.

Receive CMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CMRX
CUSIPN/A
Phone919-806-1074

Debt

Debt-to-Equity RatioN/A
Current Ratio16.99%
Quick Ratio16.99%

Price-To-Earnings

Trailing P/E Ratio-3.44053538087146
Forward P/E Ratio-3.13
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.70 million
Price / Sales40.68
Cash FlowN/A
Price / CashN/A
Book Value$5.96 per share
Price / Book0.83

Profitability

Trailing EPS($1.43)
Net Income$-76,390,000.00
Net Margins-1,440.67%
Return on Equity-26.00%
Return on Assets-25.10%

Miscellaneous

Employees87
Outstanding Shares47,130,000

Chimerix (NASDAQ:CMRX) Frequently Asked Questions

What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

How were Chimerix's earnings last quarter?

Chimerix Inc (NASDAQ:CMRX) released its earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.06. The biopharmaceutical company earned $0.90 million during the quarter, compared to analysts' expectations of $0.81 million. Chimerix had a negative net margin of 1,440.67% and a negative return on equity of 26.00%. View Chimerix's Earnings History.

When will Chimerix make its next earnings announcement?

Chimerix is scheduled to release their next quarterly earnings announcement on Wednesday, February, 28th 2018. View Earnings Estimates for Chimerix.

Where is Chimerix's stock going? Where will Chimerix's stock price be in 2018?

4 Wall Street analysts have issued 1 year price targets for Chimerix's shares. Their predictions range from $6.00 to $10.00. On average, they expect Chimerix's stock price to reach $7.67 in the next twelve months. View Analyst Ratings for Chimerix.

What are Wall Street analysts saying about Chimerix stock?

Here are some recent quotes from research analysts about Chimerix stock:

  • 1. According to Zacks Investment Research, "Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. " (1/22/2018)
  • 2. FBR & Co analysts commented, "We attended Chimerix’s Investor/Analyst Day on April 27 in New York and came away looking forward to further clinical development in 2017 and 2018. Chimerix reported data from the single ascending dose (SAD) study with IV brincidofovir (BCV) and provided additional details on future clinical trials." (5/1/2017)
  • 3. Cowen Inc analysts commented, "CMRX is developing brincidofovir as an inhibitor of several DNA viruses." (4/28/2017)

Who are some of Chimerix's key competitors?

Who are Chimerix's key executives?

Chimerix's management team includes the folowing people:

  • Ernest B. Mario Ph.D., Independent Chairman of the Board (Age 78)
  • Michelle Berrey M.D., President, Chief Executive Officer, Chief Medical Officer, Director (Age 48)
  • Timothy W. Trost CPA, Chief Financial Officer, Senior Vice President, Corporate Secretary (Age 56)
  • Roy W. Ware Ph.D., Chief Manufacturing and Technology Officer
  • Heather Knight-Trent, Vice President - Regulatory Affairs
  • Randall Lanier Ph.D., Chief Science Officer
  • W. Garrett Nichols M.D., Chief Medical Officer (Age 46)
  • Linda M. Richardson, Chief Strategy and Commercial Officer (Age 51)
  • James M. Daly, Independent Director (Age 55)
  • Martha J. Demski, Independent Director (Age 64)

Who owns Chimerix stock?

Chimerix's stock is owned by a number of of institutional and retail investors. Top institutional investors include Redmile Group LLC (8.13%), BlackRock Inc. (7.49%), ArrowMark Colorado Holdings LLC (5.75%), Prosight Management LP (3.14%), Ascend Capital LLC (1.48%) and Opaleye Management Inc. (1.27%). Company insiders that own Chimerix stock include Ernest Mario, John M Leonard, Linda M Richardson, M Michelle Berrey and Martha J Demski. View Institutional Ownership Trends for Chimerix.

Who sold Chimerix stock? Who is selling Chimerix stock?

Chimerix's stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Redmile Group LLC, Citadel Advisors LLC, TIAA CREF Investment Management LLC, Bank of New York Mellon Corp, Wells Fargo & Company MN, Teachers Advisors LLC and QS Investors LLC. View Insider Buying and Selling for Chimerix.

Who bought Chimerix stock? Who is buying Chimerix stock?

Chimerix's stock was purchased by a variety of institutional investors in the last quarter, including Prosight Management LP, ArrowMark Colorado Holdings LLC, BlackRock Inc., Ascend Capital LLC, Two Sigma Investments LP, Two Sigma Advisers LP, Renaissance Technologies LLC and Acadian Asset Management LLC. Company insiders that have bought Chimerix stock in the last two years include Ernest Mario, M Michelle Berrey and Martha J Demski. View Insider Buying and Selling for Chimerix.

How do I buy Chimerix stock?

Shares of Chimerix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chimerix's stock price today?

One share of Chimerix stock can currently be purchased for approximately $4.92.

How big of a company is Chimerix?

Chimerix has a market capitalization of $234.23 million and generates $5.70 million in revenue each year. The biopharmaceutical company earns $-76,390,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Chimerix employs 87 workers across the globe.

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]


MarketBeat Community Rating for Chimerix (CMRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  224 (Vote Outperform)
Underperform Votes:  212 (Vote Underperform)
Total Votes:  436
MarketBeat's community ratings are surveys of what our community members think about Chimerix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Chimerix (NASDAQ:CMRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 1 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.67$6.50$6.50$6.50
Price Target Upside: 55.51% upside9.70% upside9.70% upside9.70% upside

Chimerix (NASDAQ:CMRX) Consensus Price Target History

Price Target History for Chimerix (NASDAQ:CMRX)

Chimerix (NASDAQ:CMRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/14/2018JPMorgan Chase & Co.DowngradeNeutral -> UnderweightLowView Rating Details
2/2/2018HC WainwrightInitiated CoverageBuy -> Buy$10.00LowView Rating Details
5/1/2017FBR & CoReiterated RatingHold$7.00HighView Rating Details
4/28/2017CowenReiterated RatingHold$6.00LowView Rating Details
8/18/2016Piper Jaffray CompaniesSet Price TargetBuy$12.00N/AView Rating Details
3/1/2016CitigroupReiterated RatingHoldN/AView Rating Details
2/23/2016William BlairLower Price TargetMarket Perform$12.00 -> $8.00N/AView Rating Details
2/23/2016BarclaysDowngradeOverweight -> Equal Weight$12.00 -> $6.00N/AView Rating Details
2/22/2016Morgan StanleyDowngradeEqual Weight -> Underweight$8.00 -> $5.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Chimerix (NASDAQ:CMRX) Earnings History and Estimates Chart

Earnings by Quarter for Chimerix (NASDAQ:CMRX)

Chimerix (NASDAQ CMRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2018($0.49)N/AView Earnings Details
11/8/2017Q3 2017($0.43)($0.37)$0.81 million$0.90 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.41)($0.36)$1.28 million$0.68 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.37)($0.38)$1.56 million$1.08 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.37)($0.32)$0.89 million$1.98 millionViewListenView Earnings Details
11/7/2016Q3($0.39)($0.37)$1.73 million$0.65 millionViewListenView Earnings Details
8/8/2016Q2($0.51)($0.39)$1.98 million$1.80 millionViewN/AView Earnings Details
5/9/2016Q1($0.66)($0.57)$2.79 million$1.20 millionViewN/AView Earnings Details
2/29/2016Q415($0.14)($0.82)$8.07 million$3.10 millionViewListenView Earnings Details
11/5/2015Q315($0.59)($0.70)$5.01 million$2.27 millionViewListenView Earnings Details
8/6/2015Q215($0.58)($0.59)$1.37 million$4.10 millionViewListenView Earnings Details
5/11/2015Q115($0.59)($0.54)$1.19 million$1.20 millionViewListenView Earnings Details
3/6/2015Q414($0.51)($0.52)$1.13 million$1.16 millionViewListenView Earnings Details
11/7/2014Q314($0.41)($0.47)$0.40 million$1.19 millionViewN/AView Earnings Details
8/7/2014Q214($0.46)($0.39)$0.84 million$0.92 millionViewN/AView Earnings Details
5/9/2014Q1 14($0.36)($0.39)$0.85 million$0.78 millionViewN/AView Earnings Details
3/7/2014Q413($0.41)($0.31)$1.19 million$0.88 millionViewN/AView Earnings Details
11/14/2013Q3($0.38)($0.26)$1.28 million$0.91 millionViewListenView Earnings Details
8/14/2013Q2 2013($0.40)($0.91)$1.91 million$0.81 millionViewN/AView Earnings Details
5/13/2013Q1 2013($2.43)($22.58)$1.00 million$1.80 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Chimerix (NASDAQ:CMRX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.88)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.44)($0.44)($0.44)
Q2 20181($0.45)($0.45)($0.45)
Q3 20181($0.47)($0.47)($0.47)
Q4 20181$0.48$0.48$0.48
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Chimerix (NASDAQ:CMRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Chimerix (NASDAQ CMRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.50%
Institutional Ownership Percentage: 72.69%
Insider Trades by Quarter for Chimerix (NASDAQ:CMRX)
Institutional Ownership by Quarter for Chimerix (NASDAQ:CMRX)

Chimerix (NASDAQ CMRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/1/2017Linda M RichardsonInsiderSell19,833$4.47$88,653.51View SEC Filing  
12/28/2016Ernest MarioDirectorSell100,000$4.64$464,000.0012,905View SEC Filing  
9/15/2016John M LeonardDirectorSell5,000$5.03$25,150.00View SEC Filing  
8/29/2016M Michelle BerreyInsiderBuy22,417$4.47$100,203.99281,238View SEC Filing  
6/24/2016Ernest MarioDirectorBuy50,000$3.70$185,000.00381,440View SEC Filing  
6/24/2016M Michelle BerreyCEOBuy13,188$3.69$48,663.72258,821View SEC Filing  
5/13/2016Ernest MarioDirectorBuy10,000$4.53$45,300.00331,440View SEC Filing  
5/11/2016Ernest MarioDirectorBuy25,000$4.85$121,250.00297,240View SEC Filing  
5/10/2016Ernest MarioDirectorBuy800$4.76$3,808.00297,240View SEC Filing  
3/16/2016Ernest MarioDirectorBuy25,000$5.06$126,500.00287,919View SEC Filing  
3/15/2016Ernest MarioDirectorBuy20,000$5.13$102,600.00287,919View SEC Filing  
3/1/2016Martha J DemskiDirectorBuy10,000$4.89$48,900.0010,000View SEC Filing  
12/29/2015Ernest MarioDirectorBuy125,000$7.09$886,250.00262,637View SEC Filing  
11/2/2015Martha J. DemskiDirectorSell1,126$41.35$46,560.10View SEC Filing  
10/1/2015Martha J. DemskiDirectorSell2,000$37.68$75,360.00View SEC Filing  
9/1/2015Martha J. DemskiDirectorSell2,000$48.18$96,360.00View SEC Filing  
8/21/2015John M LeonardDirectorBuy1,000$47.38$47,380.004,000View SEC Filing  
7/17/2015Timothy W TrostCFOSell28,000$50.00$1,400,000.00View SEC Filing  
7/1/2015Martha J DemskiDirectorSell2,000$46.03$92,060.00View SEC Filing  
6/1/2015Martha J DemskiDirectorSell2,000$41.58$83,160.00View SEC Filing  
5/1/2015Martha J DemskiDirectorSell2,000$34.71$69,420.00View SEC Filing  
3/2/2015Martha J DemskiDirectorSell2,000$40.18$80,360.00View SEC Filing  
2/2/2015Martha J DemskiDirectorSell2,000$38.38$76,760.00View SEC Filing  
1/2/2015Martha J DemskiDirectorSell2,000$41.08$82,160.00View SEC Filing  
11/5/2014John M LeonardDirectorBuy4,000$29.00$116,000.00View SEC Filing  
9/25/2014Timothy W TrostCFOSell5,000$27.75$138,750.00View SEC Filing  
9/11/2014James NiedelDirectorSell1,099,949$29.39$32,327,501.11View SEC Filing  
9/9/2014Sanderling Venture Partners V,Major ShareholderSell122,950$29.28$3,599,976.00View SEC Filing  
9/8/2014Timothy WollaegerDirectorSell100,000$24.54$2,454,000.00View SEC Filing  
9/5/2014Ernest MarioDirectorBuy10,000$23.19$231,900.00View SEC Filing  
8/25/2014Timothy W TrostCFOSell5,000$25.13$125,650.00View SEC Filing  
7/25/2014Timothy W TrostInsiderSell5,000$22.35$111,750.00View SEC Filing  
6/25/2014Timothy W TrostCFOSell5,000$22.74$113,700.00View SEC Filing  
5/27/2014Ernest MarioDirectorBuy10,000$14.22$142,200.00View SEC Filing  
5/27/2014M Michelle BerreyInsiderBuy14,065$14.22$200,004.30View SEC Filing  
5/27/2014Timothy W TrostCFOSell5,000$17.41$87,050.00View SEC Filing  
4/25/2014Timothy W TrostInsiderSell5,000$18.67$93,350.00View SEC Filing  
3/25/2014Timothy W TrostCFOSell5,000$25.37$126,850.00View SEC Filing  
2/25/2014Timothy W TrostCFOSell5,000$19.29$96,450.00View SEC Filing  
1/27/2014Timothy W TrostCFOSell5,000$18.26$91,300.00View SEC Filing  
12/26/2013Timothy W TrostCFOSell5,000$15.21$76,050.00View SEC Filing  
12/13/2013Ernest MarioDirectorBuy5,000$13.90$69,500.00View SEC Filing  
12/9/2013Rodman L DrakeDirectorBuy1,000$14.35$14,350.00View SEC Filing  
11/25/2013Ernest MarioDirectorBuy8,000$15.20$121,600.00View SEC Filing  
11/19/2013Ernest MarioDirectorBuy7,500$15.25$114,375.00View SEC Filing  
11/15/2013Rodman L DrakeDirectorBuy1,000$15.56$15,560.00View SEC Filing  
10/25/2013Timothy W TrostCFOSell5,000$16.04$80,200.00View SEC Filing  
10/23/2013Leaf Ventures Ii L.P. NewMajor ShareholderSell585,602$15.51$9,082,687.02View SEC Filing  
10/23/2013Vii L P CanaanDirectorSell674,771$15.51$10,465,698.21View SEC Filing  
8/30/2013Ernest MarioDirectorBuy5,064$15.82$80,112.48View SEC Filing  
8/26/2013Ernest MarioDirectorBuy5,960$17.20$102,512.00View SEC Filing  
8/23/2013M Michelle BerreyInsiderBuy5,540$18.70$103,598.00View SEC Filing  
8/20/2013Ernest MarioDirectorBuy4,040$17.48$70,619.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Chimerix (NASDAQ CMRX) News Headlines

Source:
DateHeadline
Chimerix to Announce Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018Chimerix to Announce Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018
finance.yahoo.com - February 22 at 9:14 AM
 Analysts Anticipate Chimerix Inc (CMRX) Will Announce Quarterly Sales of $830,000.00 Analysts Anticipate Chimerix Inc (CMRX) Will Announce Quarterly Sales of $830,000.00
www.americanbankingnews.com - February 21 at 6:54 AM
Chimerix (CMRX) Scheduled to Post Quarterly Earnings on WednesdayChimerix (CMRX) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 21 at 2:22 AM
Chimerix (CMRX) Lowered to "Underweight" at JPMorgan Chase & Co.Chimerix (CMRX) Lowered to "Underweight" at JPMorgan Chase & Co.
www.americanbankingnews.com - February 14 at 10:40 PM
Chimerix Inc (CMRX) Receives Average Recommendation of "Hold" from BrokeragesChimerix Inc (CMRX) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 14 at 11:06 AM
Chimerix Inc (CMRX) Expected to Post Quarterly Sales of $810,000.00Chimerix Inc (CMRX) Expected to Post Quarterly Sales of $810,000.00
www.americanbankingnews.com - February 4 at 4:54 AM
HC Wainwright Begins Coverage on Chimerix (CMRX)HC Wainwright Begins Coverage on Chimerix (CMRX)
www.americanbankingnews.com - February 3 at 2:52 PM
Chimerix Inc (CMRX) Expected to Post Earnings of -$0.49 Per ShareChimerix Inc (CMRX) Expected to Post Earnings of -$0.49 Per Share
www.americanbankingnews.com - February 2 at 3:28 PM
Chimerix (CMRX) Downgraded by Zacks Investment ResearchChimerix (CMRX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 22 at 9:18 PM
Zacks: Analysts Anticipate Chimerix Inc (CMRX) Will Post Quarterly Sales of $810,000.00Zacks: Analysts Anticipate Chimerix Inc (CMRX) Will Post Quarterly Sales of $810,000.00
www.americanbankingnews.com - January 18 at 4:38 AM
-$0.49 Earnings Per Share Expected for Chimerix Inc (CMRX) This Quarter-$0.49 Earnings Per Share Expected for Chimerix Inc (CMRX) This Quarter
www.americanbankingnews.com - January 16 at 5:08 PM
Chimerix (CMRX) Cut to Sell at Zacks Investment ResearchChimerix (CMRX) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - January 9 at 7:12 PM
Wired News – Chimerix Announced Initiation of AdAPT Study for Oral Brincidofovir and Advancement of IV Brincidofovir to Phase-2 StudiesWired News – Chimerix Announced Initiation of AdAPT Study for Oral Brincidofovir and Advancement of IV Brincidofovir to Phase-2 Studies
finance.yahoo.com - January 8 at 10:05 AM
BRIEF-Chimerix Initiates Adapt Study For Oral BrincidofovirBRIEF-Chimerix Initiates Adapt Study For Oral Brincidofovir
www.reuters.com - January 5 at 4:48 PM
Recent Analysis Shows Chimerix, Highwoods Properties, HubSpot, Biglari, IDEXX Laboratories, and Argan Market Influences — Renewed Outlook, Key Drivers of GrowthRecent Analysis Shows Chimerix, Highwoods Properties, HubSpot, Biglari, IDEXX Laboratories, and Argan Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - January 5 at 9:56 AM
Chimerix Initiates AdAPT Study for Oral Brincidofovir and Advances IV Brincidofovir to Patient StudiesChimerix Initiates AdAPT Study for Oral Brincidofovir and Advances IV Brincidofovir to Patient Studies
finance.yahoo.com - January 5 at 9:56 AM
Chimerix to Present at the 36th Annual J.P. Morgan Healthcare ConferenceChimerix to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 5:06 PM
Chimerix Inc (CMRX) Short Interest UpdateChimerix Inc (CMRX) Short Interest Update
www.americanbankingnews.com - January 1 at 3:07 AM
Chimerix Inc (CMRX) Expected to Announce Quarterly Sales of $810,000.00Chimerix Inc (CMRX) Expected to Announce Quarterly Sales of $810,000.00
www.americanbankingnews.com - January 1 at 3:00 AM
 Brokerages Anticipate Chimerix Inc (CMRX) Will Announce Earnings of -$0.49 Per Share Brokerages Anticipate Chimerix Inc (CMRX) Will Announce Earnings of -$0.49 Per Share
www.americanbankingnews.com - December 30 at 9:14 PM
Head-To-Head Comparison: GlycoMimetics (GLYC) versus Chimerix (CMRX)Head-To-Head Comparison: GlycoMimetics (GLYC) versus Chimerix (CMRX)
www.americanbankingnews.com - December 30 at 1:18 PM
ETFs with exposure to Chimerix, Inc. : December 28, 2017ETFs with exposure to Chimerix, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 3:41 PM
Chimerix, Inc. :CMRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017Chimerix, Inc. :CMRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 28 at 5:28 AM
Zacks: Brokerages Anticipate Chimerix, Inc. (CMRX) Will Post Quarterly Sales of $810,000.00Zacks: Brokerages Anticipate Chimerix, Inc. (CMRX) Will Post Quarterly Sales of $810,000.00
www.americanbankingnews.com - December 15 at 3:56 AM
Chimerix, Inc. (CMRX) Expected to Announce Earnings of -$0.49 Per ShareChimerix, Inc. (CMRX) Expected to Announce Earnings of -$0.49 Per Share
www.americanbankingnews.com - December 13 at 5:36 PM
Comparing Chimerix (CMRX) and Array BioPharma (ARRY)Comparing Chimerix (CMRX) and Array BioPharma (ARRY)
www.americanbankingnews.com - December 10 at 5:20 PM
Chimerix, Inc. (CMRX) Insider Sells $88,653.51 in StockChimerix, Inc. (CMRX) Insider Sells $88,653.51 in Stock
www.americanbankingnews.com - December 5 at 7:14 PM
Chimerix Becomes Oversold (CMRX)Chimerix Becomes Oversold (CMRX)
www.thestreet.com - November 14 at 5:50 PM
Chimerix, Inc. (CMRX) Stock Rating Lowered by Zacks Investment ResearchChimerix, Inc. (CMRX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - November 13 at 5:55 PM
Chimerix, Inc. (CMRX) Lifted to "Buy" at Zacks Investment ResearchChimerix, Inc. (CMRX) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - November 11 at 8:58 PM
Chimerixs (CMRX) CEO Michelle Berrey on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaChimerix's (CMRX) CEO Michelle Berrey on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 10 at 9:43 AM
FY2017 EPS Estimates for Chimerix, Inc. (CMRX) Boosted by William BlairFY2017 EPS Estimates for Chimerix, Inc. (CMRX) Boosted by William Blair
www.americanbankingnews.com - November 10 at 7:26 AM
Chimerix, Inc. (CMRX) Cut to Strong Sell at ValuEngineChimerix, Inc. (CMRX) Cut to Strong Sell at ValuEngine
www.americanbankingnews.com - November 10 at 12:58 AM
Chimerix, Inc. (CMRX) Issues Quarterly  Earnings ResultsChimerix, Inc. (CMRX) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 9 at 6:55 PM
Chimerix (CMRX) vs. GW Pharmaceuticals PLC (GWPH) Financial ReviewChimerix (CMRX) vs. GW Pharmaceuticals PLC (GWPH) Financial Review
www.americanbankingnews.com - November 9 at 5:28 PM
$1.08 Million in Sales Expected for Chimerix, Inc. (CMRX) This Quarter$1.08 Million in Sales Expected for Chimerix, Inc. (CMRX) This Quarter
www.americanbankingnews.com - November 9 at 2:03 PM
William Blair Weighs in on Chimerix, Inc.s Q1 2018 Earnings (CMRX)William Blair Weighs in on Chimerix, Inc.'s Q1 2018 Earnings (CMRX)
www.americanbankingnews.com - November 9 at 11:46 AM
Chimerix, Inc. to Host Earnings CallChimerix, Inc. to Host Earnings Call
finance.yahoo.com - November 8 at 9:21 PM
Chimerix Announces Third Quarter 2017 Financial ResultsChimerix Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 8 at 9:21 PM
Chimerix reports 3Q lossChimerix reports 3Q loss
finance.yahoo.com - November 8 at 9:21 PM
Should You Buy Chimerix Inc (CMRX)?Should You Buy Chimerix Inc (CMRX)?
finance.yahoo.com - November 8 at 9:21 PM
Edited Transcript of CMRX earnings conference call or presentation 8-Nov-17 1:30pm GMTEdited Transcript of CMRX earnings conference call or presentation 8-Nov-17 1:30pm GMT
finance.yahoo.com - November 8 at 9:21 PM
Chimerix (CMRX) and Its Rivals Critical ComparisonChimerix (CMRX) and Its Rivals Critical Comparison
www.americanbankingnews.com - November 8 at 5:28 PM
Chimerix to Present at the Stifel 2017 Healthcare ConferenceChimerix to Present at the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 7 at 10:28 PM
 Analysts Expect Chimerix, Inc. (CMRX) Will Post Earnings of -$0.43 Per Share Analysts Expect Chimerix, Inc. (CMRX) Will Post Earnings of -$0.43 Per Share
www.americanbankingnews.com - November 7 at 1:24 AM
Chimerix to Announce Third Quarter 2017 Financial Results on November 8, 2017 - GlobeNewswire (press release)Chimerix to Announce Third Quarter 2017 Financial Results on November 8, 2017 - GlobeNewswire (press release)
globenewswire.com - November 1 at 6:07 PM
Chimerix to Announce Third Quarter 2017 Financial Results on November 8, 2017Chimerix to Announce Third Quarter 2017 Financial Results on November 8, 2017
finance.yahoo.com - November 1 at 6:07 PM
Chimerix, Inc. (CMRX) Set to Announce Earnings on MondayChimerix, Inc. (CMRX) Set to Announce Earnings on Monday
www.americanbankingnews.com - October 30 at 8:50 AM
$810,000.00 in Sales Expected for Chimerix, Inc. (CMRX) This Quarter$810,000.00 in Sales Expected for Chimerix, Inc. (CMRX) This Quarter
www.americanbankingnews.com - October 20 at 8:20 AM
Chimerix, Inc. (CMRX) Sees Significant Decrease in Short InterestChimerix, Inc. (CMRX) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - October 14 at 2:04 AM

SEC Filings

Chimerix (NASDAQ:CMRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Chimerix (NASDAQ:CMRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Chimerix (NASDAQ CMRX) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.